Hongbo Zhang, Beibei Zhou, Hanwen Zhang, Yuze Zhang, Ying Ouyang, Ruru Su, Xumei Tang, Yi Lei, Biao Huang
{"title":"MultiCubeNet: Multitask deep learning for molecular subtyping and prognostic prediction in gliomas.","authors":"Hongbo Zhang, Beibei Zhou, Hanwen Zhang, Yuze Zhang, Ying Ouyang, Ruru Su, Xumei Tang, Yi Lei, Biao Huang","doi":"10.1093/noajnl/vdaf079","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Gliomas, the most prevalent type of primary brain tumors, require precise molecular characterization for effective diagnosis and treatment. Despite advancements in radiomics, simultaneous prediction of key molecular markers, such as isocitrate dehydrogenase (<i>IDH</i>) mutation, <i>1p/19q</i> co-deletion, and telomerase reverse transcriptase (<i>TERT</i>) promoter mutation, along with prognosis, remains challenging. We aimed to develop and validate a deep learning (DL) model capable of simultaneously predicting key genetic molecular markers and prognosis in gliomas.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of 457 adult-type diffuse gliomas (193 training cohorts; 162 and 102 cases in SZS and The Cancer Genome Atlas (TCGA) validation cohorts, respectively). We developed MultiCubeNet, a multisequence, multiscale, multitask DL framework designed to predict <i>IDH</i> mutation, <i>1p/19q</i> co-deletion, <i>TERT</i> promoter mutation, and prognosis. Model performance was benchmarked against conventional radiomics pipelines and neuroradiologist annotations. Classification accuracy was evaluated by the area under the receiver operating characteristic curve (AUC), with prognostic performance quantified using Harrell's concordance index (C-index).</p><p><strong>Results: </strong>The median age of the patients was 49 years, and 266 were men (58.2%). The model demonstrated high efficiency in the training set, achieving AUCs of 0.966 for <i>IDH</i> mutation, 0.961 for <i>1p/19q</i> co-deletion, and 0.851 for <i>TERT</i> promoter mutation. In the external test set (SZS), the model maintained strong performance with AUCs of 0.877, 0.730, and 0.705 for <i>IDH</i> mutation, <i>1p/19q</i> co-deletion, and <i>TERT</i> promoter mutation, respectively. The performance in TCGA cohort was less optimal, with AUCs below 0.8. The framework consistently matched or exceeded both radiomics pipelines and neuroradiologists in molecular marker identification. Survival analysis revealed significant prognostic stratification across all cohorts (C-index: 0.706-0.866).</p><p><strong>Conclusions: </strong>MultiCubeNet, a multitask DL model leveraging multisequence and multiscale magnetic resonance imaging, demonstrated strong performance in predicting key molecular markers and prognosis in gliomas, thereby supporting personalized treatment approaches.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"7 1","pages":"vdaf079"},"PeriodicalIF":3.7000,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12130973/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuro-oncology advances","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/noajnl/vdaf079","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Gliomas, the most prevalent type of primary brain tumors, require precise molecular characterization for effective diagnosis and treatment. Despite advancements in radiomics, simultaneous prediction of key molecular markers, such as isocitrate dehydrogenase (IDH) mutation, 1p/19q co-deletion, and telomerase reverse transcriptase (TERT) promoter mutation, along with prognosis, remains challenging. We aimed to develop and validate a deep learning (DL) model capable of simultaneously predicting key genetic molecular markers and prognosis in gliomas.
Methods: We conducted a retrospective analysis of 457 adult-type diffuse gliomas (193 training cohorts; 162 and 102 cases in SZS and The Cancer Genome Atlas (TCGA) validation cohorts, respectively). We developed MultiCubeNet, a multisequence, multiscale, multitask DL framework designed to predict IDH mutation, 1p/19q co-deletion, TERT promoter mutation, and prognosis. Model performance was benchmarked against conventional radiomics pipelines and neuroradiologist annotations. Classification accuracy was evaluated by the area under the receiver operating characteristic curve (AUC), with prognostic performance quantified using Harrell's concordance index (C-index).
Results: The median age of the patients was 49 years, and 266 were men (58.2%). The model demonstrated high efficiency in the training set, achieving AUCs of 0.966 for IDH mutation, 0.961 for 1p/19q co-deletion, and 0.851 for TERT promoter mutation. In the external test set (SZS), the model maintained strong performance with AUCs of 0.877, 0.730, and 0.705 for IDH mutation, 1p/19q co-deletion, and TERT promoter mutation, respectively. The performance in TCGA cohort was less optimal, with AUCs below 0.8. The framework consistently matched or exceeded both radiomics pipelines and neuroradiologists in molecular marker identification. Survival analysis revealed significant prognostic stratification across all cohorts (C-index: 0.706-0.866).
Conclusions: MultiCubeNet, a multitask DL model leveraging multisequence and multiscale magnetic resonance imaging, demonstrated strong performance in predicting key molecular markers and prognosis in gliomas, thereby supporting personalized treatment approaches.
背景:胶质瘤是最常见的原发性脑肿瘤类型,需要精确的分子特征来进行有效的诊断和治疗。尽管放射组学取得了进步,但同时预测关键分子标记,如异柠檬酸脱氢酶(IDH)突变、1p/19q共缺失和端粒酶逆转录酶(TERT)启动子突变以及预后仍然具有挑战性。我们旨在开发和验证一个深度学习(DL)模型,该模型能够同时预测胶质瘤的关键遗传分子标记和预后。方法:我们对457例成人型弥漫性胶质瘤(193个训练队列;在SZS和TCGA验证队列中分别有162例和102例。我们开发了MultiCubeNet,这是一个多序列、多尺度、多任务的DL框架,旨在预测IDH突变、1p/19q共缺失、TERT启动子突变和预后。模型性能以传统放射组学管道和神经放射学家注释为基准。分类准确度采用受试者工作特征曲线下面积(AUC)评价,预后表现采用Harrell’s concordance index (C-index)量化。结果:患者中位年龄49岁,男性266例(58.2%)。该模型在训练集中表现出较高的效率,IDH突变的auc为0.966,1p/19q共缺失的auc为0.961,TERT启动子突变的auc为0.851。在外部测试集(SZS)中,该模型对IDH突变、1p/19q共缺失和TERT启动子突变的auc分别为0.877、0.730和0.705,保持了较强的表现。TCGA组的表现不太理想,auc低于0.8。该框架在分子标记识别方面始终匹配或超过放射组学管道和神经放射学家。生存分析显示在所有队列中存在显著的预后分层(c指数:0.706-0.866)。结论:MultiCubeNet是一个利用多序列和多尺度磁共振成像的多任务深度学习模型,在预测胶质瘤的关键分子标志物和预后方面表现出色,从而支持个性化治疗方法。